Company Description
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.
It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system.
The company was incorporated in 2015 and is headquartered in Irvine, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jan 30, 2025 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 423 |
| CEO | Sean Saint |
Contact Details
Address: 11 Hughes Irvine, California 92618 United States | |
| Phone | 949 427 7785 |
| Website | betabionics.com |
Stock Details
| Ticker Symbol | BBNX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1674632 |
| CUSIP Number | 08659B102 |
| ISIN Number | US08659B1026 |
| Employer ID | 47-5386878 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Sean T. Saint PE | President, Chief Executive Officer and Director |
| Stephen H. Feider | Chief Financial Officer, Treasurer and Secretary |
| Mike Mensinger | Chief Product Officer |
| David Henderson | Vice President of Operations |
| Blake Beber | Head of Investor Relations |
| Kevin Meinert | Vice President of Legal and Business Development |
| Dr. Steven Russell M.D., Ph.D. | Chief Medical Officer |
| Mark Hopman M.B.A., R.Ph. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2026 | 10-Q | Quarterly Report |
| Apr 21, 2026 | 8-K | Current Report |
| Apr 10, 2026 | ARS | Filing |
| Apr 10, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 4, 2026 | 144 | Filing |
| Mar 4, 2026 | 144 | Filing |
| Mar 4, 2026 | 144 | Filing |
| Mar 4, 2026 | 144 | Filing |